Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese HSK 1 – For Medical Students & Physicians A complete 20-lesson, 300-page Chinese HSK 1 course with a companion app in 21 languages — free forever. Arabic, Bengali, Dutch, English, Farsi, French, German, Hindi, Indonesian, Italian, Japanese, Korean, Portuguese, Russian, Spanish, Tagalog, Thai, Turkish, Ukrainian, Urdu, Vietnamese. By Bernd Sebastian Kamps and Andrea Melis

Prostate Cancer

Free Subscription Articles published in Am J Clin Oncol Retrieve available abstracts of 12 articles: HTML format

Single Articles

March 2026
1. AKIN EA, Wallner PE, Alexander S, Barry P, et al
   ACR-ACNM-ARS-SNMMI Practice Parameter for the Performance of Therapy With Radium-223 Dichloride.
   Am J Clin Oncol. 2026;49:127-135.
   PubMed     Abstract available
   
   
   June 2025
2. MCCLELLAND S 3RD, Fleming-Hall E, Smith TK, Onyewadume L, et al
   Establishing Feasibility of the Navigator-assisted Hypofractionation (NAVAH) Program to Address Radiation Therapy Access Disparities Facing African-Americans With Prostate Cancer.
   Am J Clin Oncol. 2025;48:325-326.
   PubMed    
   
   
   
3. CARMELI Y, Shpatz Y, Oren-Ivry I, Mansano A, et al
   Effect of Continuous Nutritionist-led Guidance on Bowel Preparation in Patients Undergoing Prostate Stereotactic Body Radiation Treatment With Endorectal Spacing: A Prospective Pilot Trial.
   Am J Clin Oncol. 2025;48:314-318.
   PubMed     Abstract available
   
   
   May 2025
4. SABBAH A, Delouya G, Laskine M, Taussky D, et al
   Metabolic Plasticity in Prostate Cancer: The Warburg Effect and Its Clinical Relevance.
   Am J Clin Oncol. 2025 May 15. doi: 10.1097/COC.0000000000001215.
   PubMed     Abstract available
   
   
   January 2025
5. SMITH RP, Mohammed MA, Beriwal S, Benoit RM, et al
   Prostate Brachytherapy With Cs-131: Long-term Results Compared With Published Stereotactic Body Radiotherapy Data.
   Am J Clin Oncol. 2025;48:34-37.
   PubMed     Abstract available
   
   
   November 2024
6. QURESHI Z, Fatima E, Safi A, Khanzada M, et al
   Talazoparib for the Treatment of Metastatic Castration-resistant Prostate Cancer: A Narrative Review.
   Am J Clin Oncol. 2024 Nov 25. doi: 10.1097/COC.0000000000001159.
   PubMed     Abstract available
   
   
   October 2024
7. OHAEGBULAM KC, Post CM, Farris PE, Garzotto M, et al
   Safety and Efficacy of Neoadjuvant Docetaxel and Radiotherapy in Localized High-Risk Prostate Cancer: Results From a Prospective Pilot Study.
   Am J Clin Oncol. 2024 Oct 30. doi: 10.1097/COC.0000000000001151.
   PubMed     Abstract available
   
   
   September 2024
8. RITTER AR, Prasad RN, Jhawar SR, Bazan JG, et al
   Hypofractionated Radiation Therapy: A Cross-sectional Survey Study of US Radiation Oncologists.
   Am J Clin Oncol. 2024;47:434-438.
   PubMed     Abstract available
   
   
   August 2024
9. MELLGARD G, Saffran N, Chakrani Z, McCroskery S, et al
   Performance Status and End-of-Life Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Androgen Receptor Targeted Therapy.
   Am J Clin Oncol. 2024 Aug 1. doi: 10.1097/COC.0000000000001115.
   PubMed     Abstract available
   
   
   July 2024
10. LEHRER S, Rheinstein PH
    Salbutamol, a Short Acting Beta-2 Agonist, Reduces Risk and Improves Prognosis of Prostate Cancer.
    Am J Clin Oncol. 2024 Jul 8. doi: 10.1097/COC.0000000000001134.
    PubMed     Abstract available
    
    
    February 2024
11. CHAKRANI Z, Mellgard G, Saffran N, McCroskery S, et al
    Risk Factors for Early Treatment Discontinuation Due to Toxicity Among Patients With Metastatic Castration-resistant Prostate Cancer Receiving Androgen Receptor-targeted Therapy.
    Am J Clin Oncol. 2024 Feb 12. doi: 10.1097/COC.0000000000001087.
    PubMed     Abstract available
    
    
    January 2024
12. JANOPAUL-NAYLOR JR, Koo A, Qian DC, McCall NS, et al
    Physician Assessment of ChatGPT and Bing Answers to American Cancer Society's Questions to Ask About Your Cancer.
    Am J Clin Oncol. 2024;47:17-21.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum